We are live on
!
Find out more
PCM
Pathway Capital Management Portfolio holdings
AUM
$4.3M
1-Year Est. Return
62.8%
This Fund
S&P 500
This Quarter
Est. Return
-33.35%
1 Year Est. Return
+62.8%
3 Year Est. Return
+496.35%
5 Year Est. Return
+305.57%
10 Year Est. Return
–
AUM
$18.8M
AUM Growth
-$2.12M
(-10%)
Cap. Flow
+$1.44M
Cap. Flow
% of AUM
7.65%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
3
Increased
–
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$7.15M |
| 2 |
Roblox
RBLX
|
+$4.79M |
| 3 |
ASTR
Astra Space, Inc. Class A Common Stock
ASTR
|
+$1.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$6.27M |
| 2 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$4.08M |
| 3 |
BILL Holdings
BILL
|
+$1.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.44% |
| 2 | Healthcare | 31.56% |
| 3 | Communication Services | 19.54% |
| 4 | Consumer Discretionary | 5.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BILL Holdings
BILL
$4.45B
| $8.15M | 43.44% |
35,937
-6,306
| -15% | -$1.31M |
|
|
2
Ginkgo Bioworks
DNA
$517M
| $5.92M | 31.56% |
+36,735
| New | +$7.15M |
|
|
3
Roblox
RBLX
$37B
| $3.67M | 19.54% |
+79,305
| New | +$4.79M |
|
|
ASTR
4
DELISTED
Astra Space, Inc. Class A Common Stock
ASTR
| $1.02M | 5.45% |
+17,666
| New | +$1.17M |
|
|
5
Arvinas
ARVN
$517M
| – | – |
-76,335
| Closed | -$6.27M |
|
|
DAWN
6
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-242,245
| Closed | -$4.08M |
|
Similar funds
CC
RA
ABA
UOMF
EAMS
KAM
FWA
RCP
Pathway Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Pathway Capital Management held 6 positions worth $18.8M, down 10% from $20.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Pathway Capital Management deployed $1.44M of net new capital in Q1 2022, opening 3 new positions. Its largest new stake was Ginkgo Bioworks: 36,735 shares worth $5.92M.
By sector, the portfolio is most concentrated in Technology at 43% of assets, down from 50% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was BILL Holdings, an estimated $1.31M trimmed.
- Pathway Capital Management's largest Q1 2022 buy was Ginkgo Bioworks: 36,735 shares worth $5.92M.
- Pathway Capital Management's biggest Q1 2022 reduction was BILL Holdings, cutting an estimated $1.31M.
- Pathway Capital Management fully exited Arvinas in Q1 2022, selling an estimated $6.27M.
- Pathway Capital Management's ten largest holdings make up 100% of its $18.8M portfolio in Q1 2022.
- Pathway Capital Management opened 3 new positions and closed 2 in Q1 2022.
- Pathway Capital Management's portfolio value fell 10% quarter-over-quarter to $18.8M.
Based on Pathway Capital Management's 13F filing for Q1 2022, filed 10 May 2022.